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Background: Acute kidney injury (AKI) is a common complication in the critically ill patients and associated with a
substantial morbidity and mortality. Severe AKI may be associated with up to 60% hospital mortality. Over the years,
renal replacement therapy (RRT) has emerged as the mainstay of the treatment for AKI. However, the exact timing
of initiation of RRT for better patient outcome is still debatable with conflicting data from randomized controlled
trials. Thus, a systematic review and meta-analysis was performed to assess the impact of “early” versus “late”
initiation of RRT.
Methods: All the published literature through the major databases including Medline/Pubmed, Embase, and
Google Scholar were searched from 1970 to October 2016. Reference lists from the articles were reviewed to
identify additional pertinent articles. Retrieved papers concerning the effect of “early/prophylactic” RRT versus “late/
as and when required” RRT were reviewed by the authors, and the data were extracted using a standardized data
collection tool. Randomized trials (RCTs) comparing early initiation of RRT or prophylactic RRT with late or as and
when required RRT were included. The primary outcome measures were all cause mortality and dialysis
dependence on day 90. The secondary outcome measures were: length of ICU stay, length of hospital stay,
recovery of renal function and adverse events.
Results: Of the 547 citation retrieved, full text of 44 articles was assessed for eligibility. Of these a total of 10 RCTs
with 1,636 participants were included. All the trials were open label; six trials have unclear or high risk of bias for
allocation concealment while four trials have low risk of bias for allocation concealment. There was a variable
definition of early versus late in different studies. Thus, the definition of early or late was taken according to
individual study definition. Compared to late RRT, there was no significant benefit of early RRT on day 30 mortality
[6 studies; 1301 participants; RR, 0.92;95% CI: 0.76, 1.12); day 60 mortality [3 trials;1075 participants; RR, 0.94; 95% CI:
0.78, 1.14)]; day 90 mortality [3 trials; 555 participants; RR,0.94;95% CI: 0.67, 1.33)]; overall ICU or hospital mortality;
dialysis dependence on day 90 [3 trials; (RR, 1.06; 95% CI:0.53, 2.12)]. There was no significant difference between
length of ICU or hospital stay or recovery of renal functions. A subgroup analysis based on modality of RRT or
mixed medical and surgical vs. surgical or based on severity of illness showed no difference in outcome measure.
The trials with high or unclear risk of bias for allocation concealment showed benefit of early RRT (RR, 0.74; 95% CI:
0.59, 0.91) while the trials with low risk of bias for allocation concealment showed no difference in the mortality (RR,
1.02; 95% CI: 0.89, 1.17). Grade evidence generated for most of the outcomes was “low quality”.
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Conclusion: This updated meta-analysis showed no added benefit of early initiation of RRT for patients with AKI.
The grade evidence generated was of “low quality” and there was a high heterogeneity in the included trials.
PROSPERO registration number: CRD42016043092.
Keywords: Acute kidney Injury (AKI), Renal replacement therapy (RRT), TimingBackground
Acute kidney injury (AKI) is a common complication in
the critically ill patients and associated with a substantial
morbidity and mortality [1–3]. Severe AKI may be asso-
ciated with up to 60% hospital mortality [4]. Over the
years, renal replacement therapy (RRT) has emerged as
the mainstay of the treatment for AKI. Intermittent
hemodialysis (IHD), peritoneal dialysis (PD) and con-
tinues renal replacement therapy (CRRT) are various
modalities to conduct RRT. Early initiation of RRT helps
in the removal of uremic toxins, allow fluid and electro-
lyte balance and prevent life threatening complications
such as metabolic encephalopathy, hyperkalemia, pul-
monary oedema [5].
The timing of initiation of RRT for better patient out-
come is still debatable with conflicting data from ran-
domized controlled trials [6–9]. Two meta-analysis
concluded that early RRT improves survival in critically
ill patients [10, 11] . However, a recent meta-analysis
[12] concluded that “early” initiation of RRT in critical
illness complicated by AKI does not improve patient
survival or confer reductions in intensive care unit
(ICU) or hospital length of stay (LOS). This meta-
analysis included both RCTs, and cohort studies. More-
over, after publication of this meta-analysis, two large
studies have been published. We conducted an updated
systematic review including RCTs and Quasi-RCTs (no
observational studies) to support or refute the earlier
evidence on the initiation of early versus late RRT. We
have also performed a robust subgroup and sensitivity
analysis as well as graded the quality of evidence and
strength of recommendations by using GRADE ap-
proach which is lacking in previous systematic reviews
and metanalysis.
Objective
To evaluate the impact of “early” versus “late” initiation
of RRT.
Methods
The review has been registered at the PROSPERO regis-
ter: CRD42016043092
Type of studies
Randomized controlled trials and quasi-randomized tri-
als (RCTs) were included.Participants
Hospitalized patients with AKI were included. Patients
with preexisting chronic kidney disease (estimated glom-
erular filtration rate [GFR] <30 mL/min) on long term
dialysis, previous renal replacement therapy, AKI result-
ing from vascular malformations (occlusion of the renal
artery), glomerulonephritis, interstitial nephritis, vascu-
litis, post-renal obstruction, hemolytic uremic syndrome
(HUS) or thrombotic thrombocytopenic purpura, post
renal transplant AKI and confirmed or suspected preg-
nancy, malignancy and HIV were excluded.
Interventions
The interventions consist of administration of early/
prophylactic or as and when required/late RRT in pa-
tients with AKI. The definition of early and late RRT
was taken as described in the individual study.
Types of outcome measures
Primary outcomes
1. Mortality rate
2. Dialysis Dependence at 3 month
Secondary outcomes
1. Length of ICU stay
2. Length of hospital stay
3. Recovery of renal function
4. Adverse events
Search methods for identification of studies
Cochrane Central Register of Controlled Trials (CEN-
TRAL), PubMed/MEDLINE, Google Scholar, Cochrane
renal group were searched from 1970 to October 2016.
Following search strategy was applied: (((((((((renal re-
placement therapy) OR Renal Dialysis) OR dialysis) OR
Hemodialysis) OR Hemodiafiltration) OR Hemofiltra-
tion)) AND (((((acute kidney injury) OR Acute Renal In-
jury) OR Acute Renal Insufficiency) OR Acute Renal
Failure) OR Acute Kidney Failure)) AND (((((((timing)
OR time) OR Initiation) OR start) OR early) OR Earlier)
OR Late)) AND ((randomized controlled trial) OR Con-
trolled Clinical Trial). To identify unpublished trial re-
sults, we searched the US National Institutes of Health,
Department of Health and Human Services trials
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International Clinical Trials Registry Platform (ICTRP)
trial registry.Data extraction
Data was extracted using a pilot tested data extraction
form. Two authors independently extract data including
author, type of participants, exposure and intervention
(modality of RRT, timing), results (clinical outcomes and
adverse events).Risk of bias (quality) assessment
Two review authors (GC and RD) independently
assessed the methodological quality of the selected trials
by using Cochrane risk of bias tool [13].Fig. 1 PRISMA flow diagramStrategy for data synthesis
The data from various studies was pooled and expressed
as mean difference (MD) with 95% confidence interval
(CI) in case of continuous data, and risk ratio (RR) with
95% CI in case of categorical data. P-value <0.05 was
considered significant. Heterogeneity was assessed by I-
squared statistics. In case of high level heterogeneity
(>50%), we tried to explore the cause. A fixed effects
model was initially conducted. If, significant heterogen-
eity was found between trials, potential sources of het-
erogeneity were considered and where appropriate, a
random effects model was used. RevMan (Review Man-
ager) version 5.3 was used for all the analyses.
Subgroup analysis
We performed the following subgroup analysis:





Participants Intervention Outcomes measured Comments
Pursnani
1997 [18]
India Number: 35 (Early RRT = 18;
Late RRT = 17
Age: Adults
Inclusion criterion: cases of
acute tubular necrosis with
creatinine <7 mg% and
blood urea <120 mg%
Exclusion criterion: cases
with creatinine >7 mg% and
urea blood urea >120 mg%.
Early RRT = Prophylactic
hemodialysis was performed





not given. Blinding and
allocation concealment not







Number: 106 patients (Early
RRT = 70; late RRT = 36
Age: 18-90 years
Inclusion: Critically ill






Early RRT = Hemofiltration
started within 12 h of
inclusion
Late RRT = Hemofiltration
started when patient fulfilled
conventional criterion for
renal replacement therapy
such as plasma urea level of
40 mmol/L, potassium of
6.5 mmol/L or severe
pulmonary edema.,
Survival at day 28 after
inclusion and recovery of
renal function, ICU survival,
hospital survival, duration of
mechanical ventilation,





were compared viz early
high volume hemofiltration,
early low volume

















Exclusion: Age less than
18 years; chronic dialysis
Early RRT = Pre-operative
prophylactic hemodialysis
was performed if serum
creatinine ≥2.5 mg/dl
Late RRT = Hemodialysis was
performed only if
postoperative acute renal
failure was seen (defined as
urine output of less than
400 mL in a 24-h period, a
50% increase in serum cre-
atinine from base line, or
need for dialysis).
Overall 30 day mortality;
mean decrease in serum
creatinine, potassium and
BUN levels; average length











Number: 28 (Early RRT = 14;





Bilirubin >5 mg/dl, mental
disorders, Cancer, Early
recovery of urine output i.e
>30 ml/kg prior to RRT
Early RRT = Dialys started if
ourly urine output <30 ml/
kg for 3 h or daily urine
output ≤750 ml .
Late RRT = Dialysis started if
hourly urine output <20 ml/
kg for 2 consecutive hours
or daily urine output
≤500 ml.
Overall 14 days mortality,
changes in the blood
pressure, changes in serum

















Early RRT = Hemofiltration
started if, clinically identified
focus on infection
associated with at least 2
systemic inflammatory
response syndrome criteria
and one or more
sepsis-induced organ failures
within the 24 h before
inclusion, plus a Simplified
Acute Physiology II score
between 35 and 63.
Control group = standard
therapy
Overall 28 day mortality;
occurrence or worsening of
sepsis induced organ failure
(SOFA score), length of ICU






Authors concluded that in
septic patients,
hemofiltration with an
ultrafiltration rate of 2 L/h







Number: 208 (Early RRT =




AKI with increasing serum
Early RRT = initiation of
dialysis therapy if serum
urea nitrogen level increased
to >70 mg/dL and/or
creatinine level increased to
>7 mg/dL irrespective of
Overall 3 months mortality,
Dialysis dependence at
3 months, increase in urine
output, decrease in blood
urea nitrogen and creatinine,
days to renal recovery,
Open label trial. Event rate
(mortality) was less than
predicted. Study population
included community
acquired AKI (different from
usual AKI population). Use of
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Table 1 Characteristics of the included studies (Continued)







fluid overload, alteration of
higher mental function
attributable to uremia, and
pericarditis), patients who
received dialysis therapy
before evaluation, and who
were judged to be in the
recovery phase.
complications till recovery of
renal functions.
Late RRT = Dialysis therapy






uremic nausea and anorexia
leading to inability to
maintain nutrient intake until
recovery


















Number = 224 (Early RRT =






shock requiring high dose
catecholamines within 24 h
following surgery.
Exclusion criterion: Younger
than 18 years old; pregnant;
previously enrolled in this or
other trials evaluating
mortality; on chronic
hemodialysis prior to heart
surgery; weight greater than
120 kg; moribund state
(defined as Simplified Acute
Physiology Score (SAPS) II




Early RRT = High volume




tion (CVVHD) till recovery of
renal function.
Late RRT/control group =
Supportive management
was provided and CVVHDF
(CVVHDF (if serum creatinine
>4 mg/dl] or threefold
increase of preoperative
values, or urine output <
0.3 ml/kg/h for 24 h despite
adequate fluid resuscitation;
serum urea > 36 mmol/L, or
life-threatening
hyperkalemia).
Overall mortality on day 30,
day 60 and day 90, ICU and









until Day 30, percentage of
patients with renal recovery
and adverse events.
Open label trial. Allocation
concealment not done. Trail
was prematurely terminated
after only 2/3rd of the
calculated enrollments. Only








Number = 101 (Early RRT
group = 48; Late RRT/control
group = 52)
Age : Adult patients
Inclusion criterion: presence
of severe AKI (defined by
the presence of two of the
following three criteria: (i) a
twofold increase in serum
creatinine from baseline, (ii)
urine output 0.6 ml/kg in
the preceding 12 h, or (iii)
whole-blood NGAL≥
400 ng/ml); [2] the absence
of urgent indications for RRT
initiation (defined as serum
potassium≤ 5.5 mmol/l and
serum bicarbonate≥
15 mmol/l); and [3] low
likelihood of volume-
responsive AKI (defined as
central venous pressure≥
8 mm Hg).
Exclusion criterion: Lack of
commitment to ongoing life
support, including RRT;
presence of an intoxication
requiring extracorporeal
removal; RRT within the
Early RRT = patients that
fulfilled inclusion criterion
were started RRT modality
based on current best
practice guidelines till death,
recovery of renal functions
or changes in goals of care.
Late RRT/Control group =
Supportive management





bicarbonate < 10 mmol/l, or
PaO2/ FiO2 < 200 with
infiltrates on chest
radiograph compatible with
pulmonary edema. RRT was
to continue until patient
death, change in goals of
care, or recovery of kidney
function. Modality selection
was based on physicians
discretion (IDH, SLED or
CRRT).
Proportion of patients in
each arm who commenced
RRT within the protocol-
specified window (≤12 and






patients followed to day 90





concealment not clear. Small
sample size
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glomerular filtration rate o
30 ml/min per 1.73 m2; and
the passage of 4 48 h since








Number: 620 (Early RRT =




with severe acute kidney
injury (KDIGO stage 3)
requiring mechanical
ventilation, catecholamine
infusion or both and did not
have potentially life
threatening complications
directly related to renal
failure.
Exclusion criterion: Age
<18 years, a blood urea
nitrogen level >112 mg per
deciliter (40 mmol per liter),
a serum potassium
concentration > 6 mmol per
liter (or greater than
5.5 mmol per liter despite
medical treatment), a pH
<7.15 in the context of
either pure metabolic
acidosis (partial pressure of
arterial carbon dioxide [Pa
co2] below 35 mm Hg) or
mixed acidosis (Pa co2 of
50 mm Hg or more without
the possibility of increasing
alveolar ventilation), and
acute pulmonary edema
due to fluid overload
responsible for severe
hypoxemia requiring an
oxygen flow rate greater
than 5 l per minute to
maintain a peripheral
capillary oxygen saturation
(Sp o2) greater than 95% or
requiring a fraction of
inspired oxygen (F io2)




Early RRT = RRT started as
soon as possible after
randomization in order for it
to be started within 6 h of
documentation of stage 3
AKI.
Late RRT = Renal-
replacement therapy was
initiated if one of the
laboratory abnormalities
defined in the exclusion
criterion developed or if
oliguria or anuria lasted for
more than 72 h after
randomization.





device setting, and anticoa-
gulation method) was left to
the discretion of each study
site and was prescribed and
monitored according to na-
tional guidelines.
Overall mortality on day 60,
receipt of renal-replacement
therapy at least once with






free days on day 28, Sepsis-
related Organ Failure Assess-
ment (SOFA) score at day 3
and day 7; the vital status at
day 28; the length of stay in
the intensive care unit and
in the hospital; the propor-




potentially related to acute
kidney injury or renal re-
placement therapy.
Open label trial. Inadequate
sample size..The patients in
the trial have advance acute
kidney injury i.e KDIGO stage
3 reducing generalizability








Number = 2319 (Early RRT =




ill patients with AKI Kidney
Disease: Improving Global
Outcomes (KDIGO) stage 2




initiated within 8 h of





Overall mortality on day 90,
mortality on day 28 and day
60,clinical evidence of organ
dysfunction determined by
SOFA scores, recovery of
renal functions, requirement
of hemodialysis after day 28
and 60, duration of renal
support, ICU and hospital
Open label trial. Allocation
concealment not clear.
Limited generalizability as




multicenter trial is needed
to confirm our results and
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Table 1 Characteristics of the included studies (Continued)
output <0.5 mL/kg/h for
12 h) and plasma neutrophil
gelatinase–associated
lipocalin level higher than
150 ng/m.
Exclusion criterion:
initiated within 12 h of
diagnosing stage 3 AKI by
KDIGO criterion or if any of
the following absolute
indications for RRT were
present: serum urea level
higher than 100 mg/dL;
serum potassium level




than 8 mEq/L (to convert to
mmol/L, multiply by 0.5);
urine production lower than
200 mL per 12 h or anuria
(according to the KDIGO
recommendations); and
organ edema in the
presence of AKI resistant to
diuretic treatment.
length of stay and markers
of inflammation.
establish the best time point
for the initiation of RRT in
critically ill patients with AKI.
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2. Modality of RRT
3. Severity of illness
4. Risk of bias for allocation concealment
Publication bias
This was looked by construction of the inverted funnel
plot as suggest by Egger et al.[14].
Grade of evidence
For assessment of the quality of evidence we used
GRADE Profiler software (version 3.2). The software
uses five parameters for rating the quality of evidence.
The parameters used were - limitations to design of
randomized controlled trials, inconsistency of results
or unexplained heterogeneity, indirectness of evidence,
imprecision of results, and publication bias. The rat-
ing was done as – no, serious, and very serious
limitation.
Results
Description of the studies
Of the 547 citation retrieved, full text of 44 articles was
assessed for eligibility (Fig. 1). Of these a total of 10
RCTs with 1,672 participants were included. Thirty three
studies were excluded due to following reasons: Non
RCT/review articles (n = 18), comparing different modal-
ities of RRT (n = 09), comparing different doses/drugs
during RRT (n = 05); Ongoing studies (n = 02). All the
trials were open label with most of the trials having un-
clear or high risk of bias for allocation concealment.
There was a variable definition of early versus late in dif-
ferent studies. Thus, the definition of early or late wastaken according to individual study definition. A sum-
mary of the studies is provided in Table 1.Primary outcome measure
Overall Mortality: Ten studies with 1672 participants re-
ported 662 deaths. Compared with the patients assigned
to late RRT, patients assigned to early RRT had 7% reduc-
tion in mortality rate. However, pooled results showed no
significant difference between the two groups (RR,
0.93;95% CI: 0.75, 1.15) (Fig. 2). Since there was a signifi-
cant heterogeneity (I2 = 50%;p = 0.17), we tried to explore
the heterogeneity based on pre-specified subgroups ana-
lysis such as: Surgical versus mixed patients, severity of ill-
ness, modality of RRT and risk of bias for allocation
concealment. We also performed a period wise mortality
analysis to address the heterogeneity in the included trials.
Day 30 mortality: This was reported in 6 trials [5, 7–9,
15, 16] with 1301 participants. The pooled results showed
8% decrease in mortality with early initiation of RRT.
However, there was no significant difference between the
early and late RRT (RR, 0.92;95% CI: 0.68, 1.06],
(Additional file 1: Figure S1 a)
Day 60 mortality: This was reported in 3 trials [8, 9,
15] with 1075 participants. The pooled results showed
no significant difference between the two strategies (RR,
0.94; 95% CI:0.78, 1.14) (Additional file 1: Figure S1a).
Day 90 mortality: This was reported in three trials [9,
15, 17] with 555 participants. The pooled results showed
no significant difference between the two strategies (RR,
0.94; 95% CI:0.67, 1.33) (Additional file 1: Figure S1a) .
Overall ICU mortality: Overall ICU mortality was re-
ported in 3 trials [7, 15, 17]. Pooled mortality showed no
significant reduction in ICU mortality with initiation of
Fig. 2 Forest plot showing overall mortality
Bhatt and Das BMC Nephrology  (2017) 18:78 Page 8 of 14early RRT (RR, 1.08; 95% CI:0.84, 1.39) (Additional file 1:
Figure S1a).
Overall hospital mortality: This was reported in 6
trials and the pooled results showed no significant
difference between the mortality rates between theFig. 3 Forest plot showing subgroup analysis based on modality of RRTtwo groups (RR, 1.07; 95% CI: 0.81, 1.42) (Additional
file 1: Figure S1a).
Dialysis Dependence at Day 90: 3 trials [6, 9, 17]
reported dialysis dependence at 90 days in the two
groups. Pooled data showed no significant difference
Bhatt and Das BMC Nephrology  (2017) 18:78 Page 9 of 14between the two groups (RR, 1.06 95% CI: 0.53, 2.12)
(Additional file 1: Figure S1c)Subgroup based on Surgical versus mixed patients
Overall 30 day mortality: 2 trials reported this outcome
[15, 16]. Overall there was no significant difference in
overall 30 day mortality (RR,0.51;95% CI: 0.09, 3.08.)
(Additional file 1: Figure S1b)
Overall 60 day mortality: Only 1 trial [15] reported this
outcome. Overall there was no significant difference be-
tween the two groups (RR, 1.14;95% CI: 0.83, 1.58)
Overall 90 day mortality: 1 trial [15] reported this outcome
without any significant difference between the two strategies.
Overall ICU: There was no significant difference be-
tween ICU (RR,1.11;95% CI:0.82, 1.52) or hospital mor-
tality (RR,1.01;95% CI:0.74, 1.36) in the surgical patients
undergoing early versus late initiation of RRT.Subgroup analysis based on severity of illness
There was no significant difference in overall day 30
mortality (5 trials, 1257 patients;RR,0.91;95% CI:0.73,
1.15);day 60 mortality (3 trials, 1075 participants; RR,
0.90; 95% CI:0.64, 1.27); day 90 mortality (3 trial, 555
participants, RR, 0.90; 95% CI:0.49, 1.64), hospital mor-
tality (RR, 1.12; 95% CI: 0.76, 1.65) and ICU mortality
(RR, 1.12;95% CI:0.75, 1.68) in critically ill undergoing
early RRT as compared to late RRT.Fig. 4 Forest plot showing subgroup based on risk of bias for allocation coSubgroup analysis based on modality of RRT
There was no significant difference in overall day 30
mortality in the patients undergoing continuous renal
replacement therapy (CRRT) (3 trials, 413 participants;
RR, 0.90;95% CI:0.65, 1.26); patients undergoing inter-
mittent hemodialysis (IHD) (1 trial,44 participants; RR,
0.16;95% CI:0.02, 1.17); patients undergoing either CRRT
or IHD (1 trial,620 participants; RR, 0.95;95% CI:0.79,
1.14): day 60 mortality in patients undergoing CRRT (2
trials, 455 participants; RR, 0.93;95% CI:0.62, 1.38) or pa-
tients undergoing either CRRT or IHD (1 trial,620 par-
ticipants; RR, 0.97;95% CI: 0.82, 1.14): day 90 mortality
in patients undergoing CRRT (2 trials, 455 participants;
RR, 0.92;95% CI:[0.56, 1.50) or patients undergoing ei-
ther CRRT or IHD (1 trial,100 participants; RR, 1.03;95%
CI:0.62, 1.71): Overall hospital mortality in the patients
undergoing CRRT (2 trials, 330 participants; RR,
1.14;95% CI:0.88, 1.48) or IHD (1 trial,44 participants;
RR, 0.16;95% CI:0.02, 1.17) and overall ICU mortality in
the patients undergoing CRRT (2 trial, 330 participants;
RR, 1.13;95% CI: 0.85, 1.49) or patients undergoing ei-
ther CRRT or IHD (1 trial, 100 participants; RR,
0.88;95% CI: 0.47, 1.63) (Fig. 3)
Subgroup analysis based on risk of bias for allocation
concealment
Six trials have low risk of bias for allocation concealment
[6, 8, 9, 15, 17] while 4 [5, 7, 16, 18, 19] have unclear orncealment
Fig. 5 Forest plot showing adverse events
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Bhatt and Das BMC Nephrology  (2017) 18:78 Page 11 of 14high risk of bias for allocation concealment. There was a
significant reduction in overall mortality in the patients
assigned to early RRT in the studies with high or unclear
risk of bias (RR, 0.74; 95% CI:0.59, 0.91) as compared to
those with low risk of bias for allocation concealment
(RR, 1.02;95% CI:0.89, 1.17) (Fig. 4)
Secondary Outcomes
Length of ICU stay: Six studies reported this outcome
[8, 9, 15–17]. Out of these, 5 trials reported this out-
come as median (interquartile range) [7–9, 15, 17] and
found no significant difference between ICU stay in the
two groups. Another trial [16] reported a significant re-
duction in ICU stay in the patients undergoing early
RRT as compared to late RRT (MD,-45.87;95% CI:-
75.54,–16.20).
Length of Hospital stay: Seven trials reported this out-
come [8, 9, 15–17] and 5 reported them as median
(Interquartile range). In 4 trials there was no significant
difference in the length of hospital stay between the two
groups while 1 trial has shown significant difference be-
tween hospital stay in patients receiving early RRT. Two
trials [7, 18] have given this outcome as mean (SD) and
were pooled. The pooled results no difference in the
length of hospital stay (MD,-3.62; 95% CI :-8.91, 16.16).
Recovery of renal function by day 90: 2 trials reported
recovery of renal functions on day 90 [9, 15]. Pooled
data showed no significant difference between two
groups (RR, 1.04;95% CI:0.80, 1.35) (Additional file 1:
Figure S1d).
Adverse events
Bleeding: 7 trials with 1520 participants reported this
outcome [6–9, 15, 17, 18]. On pooling the data no sig-
nificant difference in the adverse event was observedFig. 6 Funnel plotbetween the two groups (RR, 0.92;95% CI:0.67, 1.25)
(Fig. 5).
Catheter related complications: Four trials reported
this outcome [6, 9, 15, 17]. The pooled results showed
no significant difference between the two groups (RR,
1.41: 95% CI: 0.59, 3.37) with point estimate favouring
late strategy (Fig. 5).
Thrombocytopenia: 3 trials reported this outcome [8,
9, 17, 18] and the pooled results showed no significant
difference between the two strategies (RR,1.20:95%
CI:0.87, 1.65) (Fig. 5).
Arrhythmias: 4 trials reported this outcome [8, 9, 17, 18]
and the pooled results showed no significant difference
between the two groups (RR, 0.91;95% CI: 0.70, 1.19)
(Fig. 5).
Hypotension: 4 trials reported this outcome [6, 9, 15,
17] reported this outcome. Pooled results showed no sig-
nificant difference with point estimate favouring late
RRT (RR, 1.18; 95% CI: 1.00, 1.38) (Fig. 5).
Electrolyte abnormalities: There was no significant dif-
ference between the two strategies with respect to hypo-
kalemia (RR, 1.02;95% CI: 0.51, 2.03), hyperkalemia (RR,
0.80;95% CI: 0.45, 1.41) and hypocalcaemia (RR,
0.89;95% CI:0.51, 1.54). Hypophosphatemia was seen
more in patients undergoing early dialysis (RR, 1.51; 95%
CI: 1.05, 2.18) (Fig. 5).Publication bias
To assess whether there was a bias in the published lit-
erature, funnel plot was constructed using the MD and
1/SE values obtained from trials measuring one of the
primary outcome (overall mortality). In the absence of a
publication bias, such a plot is expected to have a shape
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Bhatt and Das BMC Nephrology  (2017) 18:78 Page 13 of 14generated, the possibility of publication bias in the ana-
lysis is less (Fig. 6).Grade of evidence
The evidence generated was of “low quality” for all the
primary outcomes (GRADE Table 2).Discussion
Summary of Evidence
After an extensive search of literature we could find 10
trials to be eligible for inclusion. Our results indicates
that in patients with AKI there is no benefit of early ini-
tiation of renal replacement therapy on overall mortality,
dialysis dependence on day 90, length of ICU or hospital
stay and renal recovery on day 90. There was no signifi-
cant difference in the adverse events between early and
late group except for hypophosphatemia which was seen
more common in the patients undergoing early RRT.
The grade evidence generated was low grade for most of
the outcomes.
Studies exploring the initiation strategies for RRT
have shown conflicting results. Early initiation of
RRT, theoretically may allow for better control of
fluid and electrolyte status, fasten removal of uremic
toxins and prevent complications like gastric
hemorrhage and metabolic encephalopathy [20]. On
the other hand a delayed strategy of RRT initiation
may give sufficient time for spontaneous patient re-
covery and may avoid the need for RRT, thus minim-
izing risk associated with RRT [9].
Two recent trials [8, 9] have also shown conflicting re-
sults regarding timing of initiation of RRT. Zarbock
et al. [9] (ELAIN trial) reported a significant reduction
of mortality over 90 days in critically ill patients with
AKI undergoing RRT while in the study by Gaudry et al.
[8] (AKIKI trial) the authors found no significant reduc-
tion in mortality in patients assigned to early RRT as
compared to late RRT. This difference may be due to
different patient’s characteristics such as inclusion of
more ill patients in the ELAIN trial as compared to that
in AKIKI trial (SOFA 16 versus SOFA 11) [21]. Another
difference was the use of RRT modality in the two stud-
ies. In the AKIKI trial 55% of the patients received inter-
mittent hemodialysis as RRT modality while all the
patients received CRRT in ELAIN trial. However, we
have done a subgroup analysis based on the modality of
RRT, severity of illness and type of patients and found
no difference in mortality rates among the two groups.
A recent systematic review has shown a benefit of early
RRT on reduction of all cause mortality [22]. However,
greater heterogeneity in the studies and a combined ana-
lysis of both RCTs and non- RCTs together may have
overestimated the effect. Further, on subgroup analysisbased on the type of studies (RCTs versus non RCTs),
authors found no statistically significant decrease in the
mortality rate in RCT group.
On subgroup analysis based on risk of bias for alloca-
tion concealment we found a significant reduction in
mortality (26%) in the patients assigned to early RRT.
Previous studies have also shown that treatment inad-
equate allocation concealment may exaggerate treatment
effect by 40% and unclear allocation concealment may
exaggerate treatment effect by 30%.
The strength of present systematic review is:1) we have
included both randomized and quasi-randomized con-
trolled trials to strengthen the present evidence2) we
have done sensitivity analysis by excluding trials with
unclear and high risk of bias for allocation conceal-
ment3) we also assigned GRADE evidence to further
grade the quality of evidence and recommendations.
Conclusion
This updated meta-analysis showed no added benefit of
early initiation of RRT for patients with AKI with respect
to all cause mortality, dialysis dependence, and recovery
of renal functions or hospital stay. The grade evidence
generated was of “low quality” and there was high het-
erogeneity in the included trials. We need more good
quality RCTs in different patient subgroups including
children to further strengthen the evidence.
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